The goal of this observational study is to register patients with plasma cell disorders. The main questions it aims to answer are: * The incidence of plasma cell disorders both before and after malignancy * Time to progression of monoclonal gammopathy of undetermined significant (MGUS) or smoldering multiple myeloma (SMM) to light chain amyloidosis or multiple myeloma (MM) * Progression free survival (PFS) * overall survival * factors influencing overall survival, progression-free survival, and time to progression * Symptoms and signs of the disease during the diagnosis and relapse phases, including the causes of mortality in plasma cell disorder patients. * genetic characteristics of plasma cell disorder * cost-effectiveness of treatment in Thailand Participants will be collected the data of baseline diagnosis, treatment, treatment results of all admission and follow-up visits from hospital medical record.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
register the plasma cell disorder patients
Timeframe: 10 years